Introduction
============

The recognition of pharmacists as healthcare providers in recent Medicare legislation is an important step in the expansion and acceptance of clinical pharmacy services.[@B1] It has been widely accepted within pharmacy organizations that pharmaceutical care should be the focus of all pharmacists.[@B2] This emphasis on pharmaceutical care and pharmacist-patient interaction is also widely noted within regulations enacted by Congress.[@B3],[@B4] There are many documented benefits of pharmacist-managed care on disease outcomes[@B5],[@B6],[@B7],[@B8],[@B9], but information related to patient perceptions of pharmacist-managed care is lacking. As previously demonstrated by Gonzalvo and colleagues, there are consistent and emerging themes related to patient perceptions of pharmacist-managed care[@B10], but there is limited guidance to help identify whether process improvement is needed in the clinical pharmacist-patient interaction. To compensate for the sparse amount of qualitative data relating to pharmacist-managed care, survey data have routinely been collected to determine patient satisfaction and perceptions of care.[@B11],[@B12]

Recognizing the subjectivity of survey results, Healthcare Failure Mode and Effect Analysis (HFMEA) is a method that has been successfully implemented to add weight to the importance of survey responses by assigning numerical value.[@B13] Traditionally, HFMEA has been used to proactively evaluate healthcare processes and identify areas for improvement or to enhance an existing service. Healthcare Failure Mode and Effect Analysis has also been used to identify a cause and effect relationship to reduce medication errors.[@B14],[@B15] HFMEA can provide a useful measure to improve clinical pharmacy services by identifying areas with the greatest impact based on what the patient values as important.

As opportunities for pharmacists continue to grow, those services offered must be evaluated to determine if they are consistent with what is valued by patients. The research noted by Knight and Caudill focused on a pharmacotherapy clinic at one Veterans Affairs Medical Center.[@B13] This study builds upon their previous work by using the HFMEA model based on surveys of patients referred to the clinical pharmacist for disease state management across multiple pharmacist-managed clinics.

The primary objective of this multicenter study was to expand upon the results of a previously piloted patient perception survey with HFMEA[@B13], to identify areas within pharmacist-managed clinics that need improvement based on patient perceptions.

Methods
=======

This study was conducted at six pharmacist-managed clinics within the central Indiana region, with data collection occurring over a six-week period between January and June 2012. Pharmacist-managed clinics were included based upon similarities in clinic location (i.e.; urban setting) and scope of clinical pharmacy services offered (i.e.; collaborative practice agreements for chronic disease management). Four of the six clinic sites generate patient charges for pharmacist appointments per their institution specific guidelines. Approval was obtained from each site's Institutional Review Board (IRB), and to maintain patient anonymity, no patient identifiers were recorded.

Survey Development
------------------

The survey utilized in this study was adapted with permission from a previously published patient perception survey and was adjusted for utilization in participating pharmacist-managed clinics. The survey was originally designed to measure patient perceptions of the quality of education provided at a single Veteran's Affairs institution.[@B13] For the current study, the survey was expanded to incorporate a variety of pharmacist-managed clinics at multiple institutions across different health systems, to identify common areas of the pharmacist-patient interaction in need of improvement. Patients were instructed to respond based on only the medications and disease states managed by the pharmacist, not all medications and disease states.

Survey Implementation
---------------------

The 27-item survey (online supplementary materialClick here for additional data file.) was distributed to six participating pharmacists for use in their pharmacist-managed clinic. Patients are referred to these pharmacist-managed clinics by their physicians for education and medication management. Each clinical pharmacist works closely with their patients and providers through a collaborative practice agreement to adjust therapies, obtain and assess necessary monitoring parameters, and help achieve desired therapeutic outcomes. The disease states managed were specific to each pharmacist-managed clinic and included anticoagulation, diabetes, hyperlipidemia, hypertension, smoking cessation, and general pharmacotherapy clinics. Patients presenting for routine follow-up in a participating pharmacist-managed clinic were eligible for inclusion, while patients under 18 years of age, had less than two prior visits with the pharmacist, or who were unable to read English were excluded from the study.

Eligible patients were recruited to participate immediately following a regularly scheduled appointment with the clinical pharmacist and were asked to complete the survey in the waiting room or empty exam room. Each patient was provided with written instructions, and completed surveys were given to reception staff within each clinic. The surveys were administered over a six week period to capture as many eligible patients as possible; however, each institution utilized a different six week period within the data collection period based on participating pharmacists' availability. Each eligible patient completed one survey during the six week study period, regardless of number of visits with the pharmacist during that time. There was no randomization or patient selection criteria other than the exclusion criteria previously defined.

Statistical Analysis
--------------------

Data were analyzed with a method adapted from that used in a HFMEA process and with standard descriptive statistical methods, to examine quality improvement results. The HFMEA is a prospective assessment that provides a method for placing weights on outcomes (i.e.: assigning a value to the importance of various components of patient education based on what the patient feels is most important). This allows for results to be prioritized and easy identification of areas for improvement based on numerical scores. For this analysis, product scores could range from a score of five to 25, with a product value of five indicating that pharmacists are doing a good job on the items that patients place the most value on while a product score of 25 would indicate that pharmacists are doing a poor job on the items that patients feel are most important. The specific steps used for calculating the HFMEA scores have been published previously13, and include scoring each survey component to be assessed, then multiplying corresponding components from sections 1 and 2 of the survey to determine an overall product score for that item. Traditionally, a product greater than one-half of the highest score is used to indicate the need for improvement when using a HFMEA method. To maintain consistency with previously published methods, a conservative final score greater than or equal to 10 was used to identify areas for improvement across the pharmacist-managed clinic sites.

Results
=======

A total of 71 patients completed surveys during the data collection period. Fifty percent of survey respondents were male, with an average age of 56±12 years ([Table 1](#T1){ref-type="table"}). Of the 13 components assessed, no item achieved a mean product of greater than or equal to ten ([Table 2](#T2){ref-type="table"}). Survey item 4, "Described the possible side effects of each of your medicines," had the highest overall mean product at 7.05. Analysis of each survey item found that all survey items had multiple individual responses that provided a product score of greater than or equal to ten ([Figure 1](#F1){ref-type="fig"}). When evaluating the survey responses based on the specific disease state managed by the pharmacist, the patients with diabetes had the highest mean product for survey item 4 with a product score of 7.5. This score was lowest at 6.3 for patients seeing the clinical pharmacist for management of warfarin therapy. Survey item 5, "Provided information about your medical problems and the benefits of treating them", had the second highest overall mean product score at 6.31. The mean product score was highest among patients seeing the pharmacist for hyperlipidemia management (mean=6.5) and lowest among patients seeing the pharmacist for warfarin management (mean=5.9). The majority of the remaining overall mean products were in the 5 to 6 point range.

###### 

Patient Demographics

  ------------------------------------------------------------------------------------------------------- ------------------
  Average age in years (SD)                                                                               56 (12)

  Gender\*                                                                                                 

  Male                                                                                                    36 (50.7%)

  Female                                                                                                  35 (49.3%)

  Ethnicity\*                                                                                              

  Hispanic or Latino                                                                                      1 (1.4%)

  Not Hispanic or Latino                                                                                  70 (98.6%)

  Race\*\*                                                                                                 

  American Indian/Alaska Native                                                                           3 (4%)

  Asian                                                                                                   1 (1.4%)

  Black/African American                                                                                  26 (37.1%)

  Native Hawaiian/Pacific Islander                                                                        0

  White/Caucasian                                                                                         40 (57.1%)

  No. of past pharmacist-managed clinic visits\*                                                           

  2                                                                                                       14 (34.1%)

  3-4                                                                                                     21 (29.6%)

  5-7                                                                                                     11 (15.5%)

  8-10                                                                                                    13 (18.3%)

  \>10                                                                                                    12 (16.9%)

  Prescription Drug coverage\*\*\*                                                                         

  Institution specific                                                                                    32 (47.8%)

  Medicaid/Medicare                                                                                       21 (31.3%)

  Private                                                                                                 6 (9.0%)

  Cash/no third party                                                                                     7 (10.4%)

  Total average no. of medications per patient (SD)+                                                      8.1 (5.3)

  Average no. of medications managed by pharmacist per patient (SD)+                                      4.2 (3.6)

  Pharmacist-managed disease state\*                                                                       

  Diabetes                                                                                                34 (47.9%)

  Warfarin (Coumadin) management                                                                          19 (26.7%)

  High blood pressure                                                                                     30 (42.2%)

  Quitting smoking                                                                                        3 (4.2%)

  High cholesterol                                                                                        42 (59.2%)

  Other                                                                                                   3 (4.2%)\*\*\*\*

  Duration of pharmacist-managed disease state in years (SD) ++                                           6.5 (7.4)

  \* n=71 \*\* n=70 \*\*\* n=67 + n=69 ++ n=65\                                                           
  \*\*\*\* Total is greater than 100% due to patients having multiple pharmacist-managed disease states   
  ------------------------------------------------------------------------------------------------------- ------------------

###### 

Survey Results

  -------------------------------------------------------------------------------------------------------------------
  Survey Item                                                                              Mean Product (IQ range)\
                                                                                           n=71
  ---------------------------------------------------------------------------------------- --------------------------
  1\. Told you the name of each of your medicines and what they are used for               5.79 (5-5)\*

  2\. Explained what your medicines do                                                     5.85 (5-5)\*

  3\. Instructed you on how you should take your medicines                                 5.83 (5-10)

  4\. Described the possible side effects of each of your medicines                        7.06 (5-10)

  5\. Provided information about your medical problems and the benefits of treating them   6.31 (5-8)

  6\. Discussed goals of treatment for each of your medical problems                       6.01 (5-7)

  7\. Talked to you about the next steps in managing your medical problems                 6.07 (5-7)

  8\. Answered your questions fully                                                        5.63 (5-5)

  9\. Discussed the resources available to help you with your medications                  6.35 (5-7)

  10\. Spent plenty of time with you                                                       5.69 (5-5)\*\*

  11\. Talked to you in a way you could easily understand                                  5.41 (5-5)

  12\. Treated you with respect and courtesy                                               5.54 (5-5)

  13\. Rating of your clinical pharmacy visits overall                                     6.01 (5-5)

  \* n=70; \*\*n=68                                                                        
  -------------------------------------------------------------------------------------------------------------------

![Figure 1. Number of Individual responses with product score ≥10 (n=71) \*n=70; \*\*n=68](pharmpract-11-196-g1){#F1}

The final non-demographic survey question asked patients to list three items they most valued. Of the 53 patients that responded, those items listed most often were "Told you the name of each of your medicines and what they are used for", "Answered your questions fully", and "Explained what your medicines do". The specific frequencies of response by survey item can be found in [Table 3](#T3){ref-type="table"}. The six items most frequently listed as being "most valued" by patients all had a mean product \<5.9. The frequency of the most valued educational components was compared between Males/Females ([Figure 2](#F2){ref-type="fig"}) and African Americans/Caucasians ([Figure 3](#F3){ref-type="fig"}). Males rated survey items 8 and 11 as most valued more often than females; females rated survey items 6, 7 and 10 as most valued more often than males. African American participants rated survey items 4, 7, 10, and 12 more often than Caucasian participants; Caucasian participants more frequently rated survey items 1, 3, and 6 compared with African American participants.

###### 

Survey Responses Listed as 1 of 3 Most Valued Items

  --------------------------------------------------------------------------------------------------------
  Survey Item                                                                          No. of Responses\
                                                                                       n = 53
  ------------------------------------------------------------------------------------ -------------------
  Told you the name of each of your medicines and what they are use for                26

  Answered your questions fully                                                        24

  Explained what your medicines do                                                     18

  Treated you with respect and courtesy                                                17

  Instructed you on how you should take your medicines                                 15

  Talked to you in a way you could easily understand                                   14

  Described the possible side effects of each of your medicines                        11

  Discussed goals of treatment for each of your medical problems                       11

  Provided information about your medical problems and the benefits of treating them   7

  Talked to you about the next steps in managing your medical problems                 7

  Spent plenty of time with you                                                        6

  Discussed the resources available to help you with your medications                  2

  Rating of your clinical pharmacy visits overall                                      1
  --------------------------------------------------------------------------------------------------------

![Figure 2. Survey responses listed as 1 of 3 most valued items (Males=27 / Females=26)](pharmpract-11-196-g2){#F2}

![Figure 3: Survey Responses Listed as 1 of 3 Most Valued Items (African American=18 / Caucasian=32)](pharmpract-11-196-g3){#F3}

Discussion
==========

The results obtained from this survey indicate that, collectively, clinical pharmacists are performing at a satisfactory level during each pharmacist-patient visit. No item achieved a product score high enough to be flagged as needing improvement based on HFMEA methods. Assessing the individual product scores has highlighted areas on which to focus future quality improvement efforts (i.e.: describing the possible side effects of each of medicine). Interestingly, these results, along with prior results[@B13], found that the individual response most commonly associated with a score of greater than or equal to ten related to the discussion of potential medication side effects. This may indicate that pharmacists working in a pharmacist-managed clinic feel it is more important to focus on overall disease state management and perhaps assume that the pharmacist dispensing the prescription will educate the patient on the medication itself, including the possible side effects. Additionally, side effects may have been discussed when medication was initiated, but not emphasized at each patient visit if no medication changes were being made. Pharmacists working in pharmacist-managed clinics should develop ways to incorporate this educational component into patient interactions.

When looking at the items frequently marked as being the most valued by patients overall, the product scores indicate that clinical pharmacists are satisfying patients' expectations across a variety of pharmacist-managed clinic settings. However, when looking at specific patient populations there are some differences in what is valued most highly during an appointment with a clinical pharmacist. Male participants more strongly valued communication in a way that could be easily understood and that fully answered questions than the female participants. The female participants placed a higher value on discussing goals of treatment and next steps of therapy, along with spending plenty of time with the patient, than did the male participants. Additionally, African American participants more frequently ranked being treated with respect and courtesy as a highly valued appointment component than did Caucasian participants, while Caucasian participants more frequently ranked being told how to take their medications. These differences among patient populations illustrate the need for continued awareness on the part of the clinician in a pharmacist-managed clinic to ensure that each patient is getting the most out of their individual appointment by including components that are most likely to be highly valued.

The results found in this study are consistent with the previously published qualitative data on pharmacist-patient interactions[@B10],[@B13] and support the idea that disease state management by pharmacists is a successful extension of care for chronic diseases. Time constraints in primary care often limit the services that can be provided by physicians.[@B16][@B17] Not only are pharmacists able to spend increased time with patients, but they are also able to do it in a way that often exceeds patient expectations of a patient-healthcare provider interaction.

The use of HFMEA as a clinical process improvement tool is a novel concept that can be applied to all aspects of pharmaceutical care, not just pharmacist-managed clinics. It is an important tool that can help pharmacists to identify areas of success as well as areas in need of improvement. An additional benefit to using the HFMEA model is its application as an important teaching tool to help increase pharmacists' self-efficacy, which may further improve patient care.

While the survey used in this research was originally designed to measure patient perceptions of the quality of pharmacist education provided at a single Veteran's Affairs institution affiliated clinics and found positive results in a small number of patients[@B13], the current study expanded the survey distribution to incorporate a variety of pharmacist-managed clinics at multiple institutions across different health systems, both Veteran's Affairs and non-Veteran's Affairs. The low number of overall participants in these studies highlights a larger challenge presented to pharmacist-managed clinics, the number of patients that do not keep their scheduled appointments. The survey was offered to each patient presenting to a pharmacist-managed clinic appointment during a six week period, unless they had already completed the survey. Patients were allowed to decline participation, but the majority of presenting patients chose to participate. The overall number of scheduled appointments during the six week survey period was significantly higher than 71. Many of the participating pharmacist-managed clinics had a patient no-show rate of greater than 50 percent, leading to a smaller than expected response rate.

The use of patient surveys as a research method is subjective by nature and open to bias. Steps were taken to minimize this bias by collecting data anonymously, allowing patients to skip questions they were not comfortable answering, and turning in completed surveys to non-pharmacy clinic staff. The study was not designed in a way to compare results between patients receiving pharmacist-managed care, and those not receiving pharmacist-managed care. As a result, no statements regarding the statistical significance of the data can be made; however, this does not limit the clinical significance or practical application of applying HFMEA results to identify areas that need improvement during a pharmacist-managed clinic appointment.

HFMEA scales are completely subjective in nature and item values are determined by those developing the scale. The authors attempted to limit subjectivity by using the same scale and analysis method that has been previously published. Additionally, HFMEA is intended to be used as a tool for process improvement. Each pharmacist's process may not be identical, introducing variables into the analysis. However, the items assessed by this survey are a part of each pharmacist-patient encounter and are similar across a variety of pharmacist-managed clinic settings. Based on the largely positive results obtained in this study, as well as the prior study by Knight and Caudill[@B13], it should be considered whether or not the HFMEA tool is sensitive enough to identify areas in need of improvement in highly functioning pharmacist-managed clinics. Further research involving both newly developed and well established pharmacist-managed clinics should be conducted to test the sensitivity and validity of this HFMEA tool.

Conclusions
===========

These results, combined with the results published by Knight and Caudill[@B13], indicate that educational components provided during pharmacist-managed clinic appointments are aligned with patients' needs and clinic based pharmacists are able to successfully incorporate the components that patients value highly in a patient-healthcare provider interaction. The HFMEA model can be utilized as an important teaching tool to identify specific processes in need of improvement and to help enhance pharmacists' self-efficacy, which may further improve patient care.
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